Explore / Clinical trial
Clinical trial

Psilocybin for Treatment-Resistant Depression

Brain and Cognition Discovery FoundationCompletedPhase 2Started Nov 19, 202130 enrolledCanadaNCT05029466

Abstract

The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve. This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants' depressive symptoms and side effects will also be measured during the study.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

Bipolar II DisorderMajor Depressive DisorderDepressive Disorder, Treatment-ResistantMood DisordersMental DisordersHallucinogenPsychedelicAntidepressantPhase 2Treatment Resistant Depression

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.